Dipyridamole for preventing stroke and other vascular events in patients with vascular disease

Quality of secondary prevention measures in TIA patients: a retrospective cohort study

“…While a combination of aspirin and dipyridamole has been shown to be more effective for the prevention of ischaemic stroke than aspirin alone,16 adverse effects leading to medication discontinuation occur in approximately 16% of patients 17. However, this does not account for the high proportion of patients not prescribed dipyridamole in this study (50%).…”

Quality of secondary prevention measures in TIA patients: a retrospective cohort study

“…While a combination of aspirin and dipyridamole has been shown to be more effective for the prevention of ischaemic stroke than aspirin alone,16 adverse effects leading to medication discontinuation occur in approximately 16% of patients 17. However, this does not account for the high proportion of patients not prescribed dipyridamole in this study (50%).…”

Effect of Dipyridamole on Experimental Autoimmune Uveitis: Reprogrammed Immune Cell Landscape and Reduced Th17 Pathogenicity

“…Moreover, DIP is orally bioavailable, which enhances patient convenience and treatment adherence. 85 Its long-standing clinical use is supported by substantial safety and efficacy data, 86 , 87 potentially offering advantages over newly developed PDE inhibitors in certain scenarios. No major immune-related adverse effects of DIP have been documented to date, supporting its safety profile.…”

Enhancing Extracellular Adenosine Levels Restores Barrier Function in Acute Lung Injury Through Expression of Focal Adhesion Proteins

“…Similar protection was also observed in mice with selective deletion of Ent2 specifically in alveolar epithelial type II cells. Dipyridamole is a FDA-approved medication used as a vasodilator for the treatment of blood clot formation and stroke (De Schryver et al, 2007;Sacco et al, 2008). Compared to mice ENTs, dipyridamole has a more potent inhibition effect on human ENTs (Yao et al, 1997), suggesting that dipyridamole could be an even more beneficial drug in the treatment of patients by lowering the off-target effects.…”

Quality of secondary prevention measures in TIA patients: a retrospective cohort study

“…While a combination of aspirin and dipyridamole has been shown to be more effective for the prevention of ischaemic stroke than aspirin alone,16 adverse effects leading to medication discontinuation occur in approximately 16% of patients 17. However, this does not account for the high proportion of patients not prescribed dipyridamole in this study (50%).…”

Effect of Dipyridamole on Experimental Autoimmune Uveitis: Reprogrammed Immune Cell Landscape and Reduced Th17 Pathogenicity

“…Moreover, DIP is orally bioavailable, which enhances patient convenience and treatment adherence. 85 Its long-standing clinical use is supported by substantial safety and efficacy data, 86 , 87 potentially offering advantages over newly developed PDE inhibitors in certain scenarios. No major immune-related adverse effects of DIP have been documented to date, supporting its safety profile.…”

Enhancing Extracellular Adenosine Levels Restores Barrier Function in Acute Lung Injury Through Expression of Focal Adhesion Proteins

“…Similar protection was also observed in mice with selective deletion of Ent2 specifically in alveolar epithelial type II cells. Dipyridamole is a FDA-approved medication used as a vasodilator for the treatment of blood clot formation and stroke (De Schryver et al, 2007;Sacco et al, 2008). Compared to mice ENTs, dipyridamole has a more potent inhibition effect on human ENTs (Yao et al, 1997), suggesting that dipyridamole could be an even more beneficial drug in the treatment of patients by lowering the off-target effects.…”

Quality of secondary prevention measures in TIA patients: a retrospective cohort study

“…While a combination of aspirin and dipyridamole has been shown to be more effective for the prevention of ischaemic stroke than aspirin alone,16 adverse effects leading to medication discontinuation occur in approximately 16% of patients 17. However, this does not account for the high proportion of patients not prescribed dipyridamole in this study (50%).…”

Effect of Dipyridamole on Experimental Autoimmune Uveitis: Reprogrammed Immune Cell Landscape and Reduced Th17 Pathogenicity

“…Moreover, DIP is orally bioavailable, which enhances patient convenience and treatment adherence. 85 Its long-standing clinical use is supported by substantial safety and efficacy data, 86 , 87 potentially offering advantages over newly developed PDE inhibitors in certain scenarios. No major immune-related adverse effects of DIP have been documented to date, supporting its safety profile.…”

Enhancing Extracellular Adenosine Levels Restores Barrier Function in Acute Lung Injury Through Expression of Focal Adhesion Proteins

“…Similar protection was also observed in mice with selective deletion of Ent2 specifically in alveolar epithelial type II cells. Dipyridamole is a FDA-approved medication used as a vasodilator for the treatment of blood clot formation and stroke (De Schryver et al, 2007;Sacco et al, 2008). Compared to mice ENTs, dipyridamole has a more potent inhibition effect on human ENTs (Yao et al, 1997), suggesting that dipyridamole could be an even more beneficial drug in the treatment of patients by lowering the off-target effects.…”